Research Solutions Reports Fiscal First Quarter 2022 Results
Research Solutions, Inc. (NASDAQ: RSSS) reported its fiscal Q1 2022 results for the quarter ended September 30, 2021. Total revenue remained steady at $7.7 million, with platform revenue rising 32% to $1.5 million. Annual recurring revenue (ARR) grew by 33% to $6.3 million, while gross profit increased 9% year-over-year. However, the company incurred a net loss of $372,000 or ($0.01) per share, compared to a net income of $15,000 in the prior-year quarter. Operating expenses increased by 24.4% to $3.0 million.
- Annual recurring revenue (ARR) increased by 33% to $6.3 million.
- Platform revenue grew by 32% to $1.5 million.
- Gross profit rose by 9% year-over-year.
- Total gross margin improved by 275 basis points to 34.4%.
- Net new platform deployments increased to 37 from 31 year-over-year.
- Net loss of $372,000 compared to net income of $15,000 in the prior-year quarter.
- Total revenue unchanged from the prior-year quarter at $7.7 million.
- Operating expenses up 24.4% to $3.0 million.
HENDERSON, Nev., Nov. 11, 2021 /PRNewswire/ -- Research Solutions, Inc. (NASDAQ: RSSS), a pioneer in providing cloud-based workflow solutions for R&D driven organizations, reported financial results for its fiscal first quarter ended September 30, 2021.
Fiscal First Quarter 2022 Summary
- Total revenue of
$7.7 million , unchanged from prior-year quarter - Platform revenue up
32% to$1.5 million . Annual Recurring Revenue ("ARR") up33% to$6.3 million . - Gross profit up
9% from prior-year quarter. Total gross margin improved 275 basis points to34.4% . - Loss of
$0.01 per share, compared to earnings of nil per diluted share in the prior-year quarter - 37 net new platform deployments in the quarter compared to 31 in the prior-year
"Our first quarter fiscal 2022 results reflect the continued focus on the growth of our Platforms business, with 37 net new deployments in the quarter and 158 deployments over the past 12 months," said Roy W. Olivier, President and CEO of Research Solutions. "The combination of product initiatives and more focused sales and marketing efforts is leading to the addition of customers brand new to the company. With additional products set for launch later this year and the ability to use our strong balance sheet to make strategic acquisitions to supplement our organic growth, we believe we are well-positioned for continued success in fiscal 2022."
Fiscal First Quarter 2022 Results
Total revenue was
Platform subscription revenue increased
Transaction revenue was
Total gross margin improved 275 basis points from the prior-year quarter to
Total operating expenses were
Net loss in the first quarter was (
Conference Call
Research Solutions Interim President and CEO Roy W. Olivier and CFO Bill Nurthen will host the conference call, followed by a question and answer period.
Date: Thursday, November 11, 2021
Time: 5:00 p.m. ET (2:00 p.m. PT)
Toll-free dial-in number: 1-844-825-9789
International dial-in number: 1-412-317-5180
Conference ID: 10161728
The conference call will be broadcast live and available for replay until December 9, 2021, by dialing 1-844-512-2921 and using the replay ID 10161728, and via the investor relations section of the company's website at http://researchsolutions.investorroom.com/.
Fiscal First Quarter Financial and Operational Summary Tables vs. Prior-Year Quarter | |||||
Quarter Ended September 30, | |||||
2021 | 2020 | Change | % Change | ||
Revenue: | |||||
Platforms | $ 368,186 | ||||
Transactions | (374,107) | - | |||
Total Revenue | 7,742,504 | 7,748,425 | (5,921) | - | |
Gross Profit: | |||||
Platforms | 1,264,218 | 937,736 | 326,482 | ||
Transactions | 1,396,157 | 1,511,840 | (115,683) | - | |
Total Gross Profit | 2,660,375 | 2,449,576 | 210,799 | ||
Gross profit as a % of revenue: | |||||
Platforms | |||||
Transactions | - | ||||
Total Gross Profit | |||||
Operating Expenses: | |||||
Sales and marketing | 522,951 | 498,374 | 24,577 | ||
Technology and product development | 821,460 | 622,961 | 198,499 | ||
General and administrative | 1,497,223 | 1,161,061 | 336,162 | ||
Depreciation and amortization | 2,896 | 3,723 | (827) | - | |
Stock-based compensation | 171,110 | 170,790 | 320 | ||
Foreign currency translation loss | 11,243 | (24,249) | 35,492 | ||
Total Operating Expenses | 3,026,883 | 2,432,660 | 594,223 | ||
Income (loss) from operations | (366,508) | 16,915 | (383,424) | - | |
Other Income (Expenses): | |||||
Other income (expense) | 276 | 235 | 41 | ||
Provision for income taxes | (5,770) | (2,505) | (3,265) | - | |
Gain on sale of disc'd operations | - | - | - | ||
Total Other Income (Expenses): | (5,494) | (2,270) | (3,224) | - | |
Net income (loss) | $ (372,002) | $ 14,645 | (386,648) | - | |
Adjusted EBITDA | $ (181,259) | $ 167,179 | $ (348,439) | - | |
Quarter Ended September 30, | |||||
2021 | 2020 | Change | % Change | ||
Platforms: | |||||
ARR (Annual recurring revenue): | |||||
Beginning of Period | |||||
Incremental ARR | 402,748 | 295,095 | 107,653 | ||
End of Period | |||||
Deployments: | |||||
Beginning of Period | 553 | 401 | 152 | ||
Incremental Deployments | 37 | 31 | 6 | ||
End of Period | 590 | 432 | 158 | ||
ASP (Average sales price): | |||||
Beginning of Period | $ 10,633 | $ 11,088 | $ (454) | - | |
End of Period | $ 10,649 | $ 10,975 | $ (326) | - | |
Transaction Customers: | |||||
Corporate customers | 853 | 805 | 48 | ||
Academic customers | 300 | 285 | 15 | ||
Total customers | 1,153 | 1,090 | 63 |
Active Customer Accounts, Transactions and Annual Recurring Revenue
The company defines active customer accounts as the sum of the total quantity of customers per month for each month in the period divided by the respective number of months in the period. The quantity of customers per month is defined as customers with at least one transaction during the month.
A transaction is an order for a unit of copyrighted content fulfilled or managed in the Platform.
The company defines annual recurring revenue ("ARR") as the value of contracted Platform subscription recurring revenue normalized to a one-year period.
Use of Non-GAAP Measure – Adjusted EBITDA
Research Solutions' management evaluates and makes operating decisions using various financial metrics. In addition to the company's GAAP results, management also considers the non-GAAP measure of Adjusted EBITDA. Management believes that this non-GAAP measure provides useful information about the company's operating results.
The tables below provide a reconciliation of this non-GAAP financial measure with the most directly comparable GAAP financial measure. Adjusted EBITDA is defined as net income (loss), plus interest expense, other income (expense), foreign currency transaction loss, provision for income taxes, depreciation and amortization, stock-based compensation, gain on sale of discontinued operations, and other potential adjustments that may arise. Set forth below is a reconciliation of Adjusted EBITDA to net income (loss):
Quarter Ended September 30, | |||||
2021 | 2020 | Change | % Change | ||
Net Income (loss) | $ (372,002) | $ 14,645 | $ (386,648) | - | |
Add (deduct): | |||||
Other income (expense) | (276) | (235) | (41) | - | |
Foreign currency translation loss | 11,243 | (24,249) | 35,492 | ||
Provision for income taxes | 5,770 | 2,505 | 3,265 | ||
Depreciation and amortization | 2,896 | 3,723 | (827) | - | |
Stock-based compensation | 171,110 | 170,790 | 320 | ||
Gain on sale of disc. ops. | - | - | - | ||
Adjusted EBITDA | $ (181,259) | $ 167,179 | $ (348,439) | - |
About Research Solutions
Research Solutions, Inc. (NASDAQ: RSSS) provides cloud-based technologies to streamline the process of obtaining, managing, and creating intellectual property. Founded in 2006 as Reprints Desk, the company was a pioneer in developing solutions to serve researchers. Today, more than 70 percent of the top pharmaceutical companies, prestigious universities, and emerging businesses rely on Article Galaxy, the company's SaaS research platform, to streamline access to the latest scientific research and data with 24/7 customer support. For more information and details, please visit www.researchsolutions.com and www.reprintsdesk.com
Important Cautions Regarding Forward-Looking Statements
Certain statements in this press release may contain "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in the Company's most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Examples of forward-looking statements in this release include statements regarding additional customers, potential acquisitions and the Company's prospects for growth. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to the Company's filings with the Securities and Exchange Commission.
Research Solutions, Inc. and Subsidiaries | |||||||
Consolidated Balance Sheets | |||||||
September 30, | |||||||
2021 | June 30, | ||||||
(unaudited) | 2021 | ||||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 10,871,336 | $ | 11,004,337 | |||
Accounts receivable, net of allowance of | 4,702,686 | 4,717,453 | |||||
Prepaid expenses and other current assets | 207,813 | 270,252 | |||||
Prepaid royalties | 265,156 | 904,921 | |||||
Total current assets | 16,046,991 | 16,896,963 | |||||
Other assets: | |||||||
Property and equipment, net of accumulated depreciation of | 21,187 | 20,755 | |||||
Deposits and other assets | 876 | 906 | |||||
Total assets | $ | 16,069,054 | $ | 16,918,624 | |||
Liabilities and Stockholders' Equity | |||||||
Current liabilities: | |||||||
Accounts payable and accrued expenses | $ | 6,461,726 | $ | 6,687,188 | |||
Deferred revenue | 4,438,591 | 4,804,351 | |||||
Total current liabilities | 10,900,317 | 11,491,539 | |||||
Commitments and contingencies | |||||||
Stockholders' equity: | |||||||
Preferred stock; | — | — | |||||
Common stock; | 26,594 | 26,498 | |||||
Additional paid-in capital | 27,098,585 | 26,982,052 | |||||
Accumulated deficit | (21,833,890) | (21,461,888) | |||||
Accumulated other comprehensive loss | (122,552) | (119,577) | |||||
Total stockholders' equity | 5,168,737 | 5,427,085 | |||||
Total liabilities and stockholders' equity | $ | 16,069,054 | $ | 16,918,624 |
Research Solutions, Inc. and Subsidiaries | |||||||
Consolidated Statements of Operations and Other Comprehensive Loss | |||||||
(Unaudited) | |||||||
Three Months Ended | |||||||
September 30, | |||||||
2021 | 2020 | ||||||
Revenue: | |||||||
Platforms | $ | 1,509,874 | $ | 1,141,688 | |||
Transactions | 6,232,630 | 6,606,737 | |||||
Total revenue | 7,742,504 | 7,748,425 | |||||
Cost of revenue: | |||||||
Platforms | 245,656 | 203,952 | |||||
Transactions | 4,836,473 | 5,094,897 | |||||
Total cost of revenue | 5,082,129 | 5,298,849 | |||||
Gross profit | 2,660,375 | 2,449,576 | |||||
Operating expenses: | |||||||
Selling, general and administrative | 3,023,987 | 2,428,938 | |||||
Depreciation and amortization | 2,896 | 3,723 | |||||
Total operating expenses | 3,026,883 | 2,432,661 | |||||
Income (loss) from operations | (366,508) | 16,915 | |||||
Other income | 276 | 235 | |||||
Income (loss) from operations before provision for income taxes | (366,232) | 17,150 | |||||
Provision for income taxes | (5,770) | (2,505) | |||||
Net income (loss) | (372,002) | 14,645 | |||||
Other comprehensive income (loss): | |||||||
Foreign currency translation | (2,975) | 1,165 | |||||
Comprehensive income (loss) | $ | (374,977) | $ | 15,810 | |||
Income (loss) per common share: | |||||||
Basic | $ | (0.01) | $ | — | |||
Diluted | $ | (0.01) | $ | — | |||
Weighted average common shares outstanding: | |||||||
Basic | 26,277,116 | 25,898,900 | |||||
Diluted | 26,277,116 | 26,511,180 |
Research Solutions, Inc. and Subsidiaries | |||||||
Consolidated Statements of Cash Flows | |||||||
(Unaudited) | |||||||
Three Months Ended | |||||||
September 30, | |||||||
2021 | 2020 | ||||||
Cash flow from operating activities: | |||||||
Net income (loss) | $ | (372,002) | $ | 14,645 | |||
Adjustment to reconcile net income (loss) to net cash provided by (used in) operating activities: | |||||||
Depreciation and amortization | 2,896 | 3,723 | |||||
Amortization of lease right | — | 30,778 | |||||
Fair value of vested stock options | 71,999 | 77,627 | |||||
Fair value of vested restricted common stock | 99,111 | 93,164 | |||||
Changes in operating assets and liabilities: | |||||||
Accounts receivable | 14,767 | (5,831) | |||||
Prepaid expenses and other current assets | 62,439 | 1,366 | |||||
Prepaid royalties | 639,765 | (322,191) | |||||
Accounts payable and accrued expenses | (225,462) | 1,032,896 | |||||
Deferred revenue | (365,760) | 31,072 | |||||
Lease liability | — | (33,776) | |||||
Net cash provided by (used in) operating activities | (72,247) | 923,473 | |||||
Cash flow from investing activities: | |||||||
Purchase of property and equipment | (3,643) | (4,304) | |||||
Net cash used in investing activities | (3,643) | (4,304) | |||||
Cash flow from financing activities: | |||||||
Proceeds from the exercise of stock options | — | 14,100 | |||||
Common stock repurchase | (54,481) | (58,395) | |||||
Net cash used in financing activities | (54,481) | (44,295) | |||||
Effect of exchange rate changes | (2,630) | 903 | |||||
Net increase (decrease) in cash and cash equivalents | (133,001) | 875,777 | |||||
Cash and cash equivalents, beginning of period | 11,004,337 | 9,311,556 | |||||
Cash and cash equivalents, end of period | $ | 10,871,336 | $ | 10,187,333 | |||
Supplemental disclosures of cash flow information: | |||||||
Cash paid for income taxes | $ | 5,770 | $ | 2,505 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/research-solutions-reports-fiscal-first-quarter-2022-results-301422579.html
SOURCE Research Solutions, Inc.
FAQ
What were the total revenues for Research Solutions in Q1 2022?
How did the platform revenue perform in the fiscal first quarter of 2022?
What is the annual recurring revenue (ARR) for Research Solutions as of Q1 2022?
What was the net loss per share for Research Solutions in Q1 2022?